US 11,951,178 B2
Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
Jianjun Chen, Cincinnati, OH (US); Seungpyo Hong, Naperville, IL (US); Xi Jiang, Cincinnati, OH (US); and Zejuan Li, Chicago, IL (US)
Assigned to University of Cincinnati, Cincinnati, OH (US); University of Chicago, Chicago, IL (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed by University of Cincinnati, Cincinnati, OH (US); The Board of Trustees of the University of Illinois, Chicago, IL (US); and The University of Chicago, Chicago, IL (US)
Filed on Jul. 14, 2021, as Appl. No. 17/375,548.
Application 17/375,548 is a division of application No. 16/310,104, granted, now 11,097,014, previously published as PCT/US2017/037424, filed on Jun. 14, 2017.
Claims priority of provisional application 62/349,707, filed on Jun. 14, 2016.
Prior Publication US 2021/0338835 A1, Nov. 4, 2021
Int. Cl. C12N 15/11 (2006.01); A61K 31/551 (2006.01); A61K 31/7105 (2006.01); A61K 38/19 (2006.01); A61K 45/06 (2006.01); A61K 47/59 (2017.01); A61K 47/62 (2017.01); A61K 47/69 (2017.01); A61P 35/02 (2006.01); C12N 15/113 (2010.01)
CPC A61K 47/6935 (2017.08) [A61K 31/551 (2013.01); A61K 31/7105 (2013.01); A61K 38/19 (2013.01); A61K 45/06 (2013.01); A61K 47/595 (2017.08); A61K 47/62 (2017.08); A61P 35/02 (2018.01); C12N 15/1138 (2013.01); C12N 2310/141 (2013.01); C12N 2310/321 (2013.01)] 16 Claims
 
1. A method of treating acute myeloid leukemia (AML) in a patient in need thereof, the method comprising: administering to the patient an FLT3-guided dendrimeric nanoparticle complexed with miR-150, wherein the FLT3-guided dendrimeric nanoparticle comprises a PAMAM dendrimer that is surface-functionalized with a ligand specific for FLT3 receptor, said ligand consists of a natural and/or synthetic FLT3L peptide having at least 90% sequence homology to SEQ ID NO: 1.